Tag: consensus

NEW YORK, July 26, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the investing public.

LUXEMBOURG, July 26, 2025 (GLOBE NEWSWIRE) -- Bitcoin Swift (BTC3), a next-generation blockchain infrastructure protocol, is approaching the final hours of Stage 1 of its presale, offering early adopters programmable Proof-of-Yield (PoY) rewards and ecosystem access at a fixed entry price of $1.00. The project has drawn attention for launching with built-in staking incentives, AI-driven governance, and a collateral-backed stablecoin—all live from day one.

LUXEMBOURG, July 26, 2025 (GLOBE NEWSWIRE) -- As investor focus shifts away from large-cap cryptocurrencies with limited upside, early-stage projects with real-world utility and scalable technology are gaining traction. One such project is Bitcoin Swift (BTC3), a next-generation blockchain protocol currently in its presale phase. With a fixed price of $1.00 during Stage 1 and a confirmed $15.00 launch target, Bitcoin Swift is positioning itself as a notable entry in the 2025 crypto landscape.

London, United Kingdom, July 26, 2025 (GLOBE NEWSWIRE) -- In response to XRP officially surpassing a $200 billion market capitalization, MGPD Finance Limited, doing business as HashJ, today announced the expansion of its mobile-based digital contract platform to further support XRP and Dogecoin-based reward systems. The platform allows everyday users to engage with the fast-growing digital asset economy—now including XRP-linked reward strategies and Dogecoin contract participation—entirely from their smartphones.

SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognify Life Sciences, a clinical-stage biotech company focused on developing treatments for cognitive impairment, today announced that its randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating inidascamine (formerly RL-007) in patients with cognitive impairment associated with schizophrenia (CIAS) did not meet its primary endpoint.

Stage 2 Will Introduce Price Increase and APY Adjustment as Project Prepares for Solana Deployment and AI-Driven Governance Rollout

NEW YORK and MAINZ, GERMANY, July 25, 2025 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for the companies’ LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY^® LP.8.1) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the EMA’s Emergency Task Force (ETF) to update COVID-19 vaccines to target the LP.8.1 variant for the 2025-2026 season. The ETF stated that “targeting LP.8.1 will help maintain the effectiveness of the vaccines as SARS-CoV-2 continues to evolve.”²

Narrows 2025 Guidance

J.D. Power Recognizes Verizon as America’s Most Awarded for Network Quality, an unprecedented 35 Times in a row